Sugi Predict

Sugi Predict / Targets / PANK3

PANK3

Pantothenate kinase 3 · Q9H999 · PANK3 on Sugi Atlas →

12,704 patent compounds predicted against PANK3, 6,270 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL1574392 SCHEMBL1574392 0.51 12/20
SCHEMBL1574445 SCHEMBL1574445 0.50 12/20
SCHEMBL104605 SCHEMBL104605 0.65 11/20
SCHEMBL1877788 SCHEMBL1877788 0.58 11/20
SCHEMBL1147398 SCHEMBL1147398 0.54 11/20
SCHEMBL2427149 SCHEMBL2427149 0.51 11/20
SCHEMBL1575844 SCHEMBL1575844 0.50 11/20
SCHEMBL1574442 SCHEMBL1574442 0.46 11/20
SCHEMBL2017867 SCHEMBL2017867 0.57 10/20
SCHEMBL388013 SCHEMBL388013 0.52 10/20
SCHEMBL1575250 SCHEMBL1575250 0.47 10/20
SCHEMBL2068254 SCHEMBL2068254 0.59 9/20
SCHEMBL940789 SCHEMBL940789 0.51 9/20
SCHEMBL1574441 SCHEMBL1574441 0.48 9/20
SCHEMBL2120919 SCHEMBL2120919 0.64 8/20
SCHEMBL1574988 SCHEMBL1574988 0.52 8/20
SCHEMBL941941 SCHEMBL941941 0.51 8/20
SCHEMBL593040 SCHEMBL593040 0.50 8/20
SCHEMBL2349007 SCHEMBL2349007 0.48 8/20
SCHEMBL1574659 SCHEMBL1574659 0.46 8/20

Clinical trials — most relevant to PANK3 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Cardiac REperfusion With Intralipid® at Reperfusion PHASE2/PHASE3UNKNOWN
Biological Effects of Quercetin in COPD Phase II PHASE2UNKNOWN
Study of BKM120 in Advanced Squamous Cell Carcinoma of Head and Neck PHASE2UNKNOWN
Biological Effects of Quercetin in COPD PHASE1/PHASE2UNKNOWN
Efficacy of Amlexanox vs. Placebo in Type 2 Diabetic Patients PHASE2COMPLETED
Everolimus for Children With Recurrent or Progressive Ependymoma PHASE2COMPLETED
A Phase II Study of EVEROLIMUS in Patients With Primary or Relapsed Chondrosarcomas PHASE2SUSPENDED
Autologous Cytokine Induced Killer Cells (CIK) for Chronic Myeloid Leukemia (CML) Patients on Standard Drug Therapy PHASE2COMPLETED
Phase II Study of Simvastatin Plus Irinotecan, Fluorouracil, and Leucovorin(FOLFIRI) for Metastatic CRC PHASE2COMPLETED
Doxycycline in Human Pulmonary Tuberculosis PHASE2COMPLETED
Perifosine in Treating Patients With Recurrent, Refractory, Locally Advanced, or Metastatic Breast Cancer PHASE2COMPLETED
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma PHASE1COMPLETED
A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of DS-6051b PHASE1COMPLETED
Phase 1a Single Ascending Dose Study of MIB-725 in Healthy Adults PHASE1RECRUITING
Single Ascending Dose Study of SAR443820 in Healthy Adult Chinese and Japanese Female and Male Participants PHASE1COMPLETED
Study of Nelfinavir and Temsirolimus in Patients With Advanced Cancers PHASE1COMPLETED
Pre-Surgical Trial of the Combination of Metformin and Atorvastatin in Newly Diagnosed Operable Breast Cancer EARLY_PHASE1COMPLETED
Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212 EARLY_PHASE1COMPLETED
p-AKT Expression on Clinical Outcomes in Malignant Lymphoma nanCOMPLETED
Dietary Ketosis: Fatty Acids Activate AMPK Energy Circuits Modulating Global Methylation nanCOMPLETED
Pancreatic Intraepithelial Neoplasia (PanIN) and the Association With Recurrence of Pancreatic Adenocarcinoma nanCOMPLETED
Investigation of Copy Number Variations and Genetic Variants in POI nanRECRUITING
Identification of a New Blood Biomarker for the Diagnosis and Prognosis of Liposarcomas nanRECRUITING
Defining the Genetic Basis for the Development of Primary Pigmented Nodular Adrenocortical Disease (PPNAD) and the Carney Complex nanCOMPLETED
Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus nanCOMPLETED
Protein Intake and Step Reduction in Older Adults nanCOMPLETED
Ischemic Preconditioning to Prevent Acute Kidney Injury nanCOMPLETED
The Phosphodiesterase-3 Inhibitor Cilostazol as an Adjunctive to Antidepressants in Patients With Major Depressive Disorder. nanCOMPLETED
Glycine and Magnesium+Thiamine for the Treatment of Primary Ciliary Dyskinesia nanRECRUITING
Genetic Predisposition Testing Program for Pancreatic Neuroendocrine Neoplasms nanRECRUITING

Related proteins — ESM-2 sequence neighbours (a PANK3 binder may also engage these)

ProteinNameSimilarity
Q8R2W9 — 1.000 Q8R2W9 →
Q08DA5 — 1.000 Q08DA5 →
P93834 — 0.999 P93834 →
Q9FZG4 — 0.998 Q9FZG4 →
Q42525 — 0.996 Q42525 →
Q2KNB7 — 0.994 Q2KNB7 →
Q9SQ76 — 0.994 Q9SQ76 →
P80581 — 0.994 P80581 →
Q04409 — 0.994 Q04409 →
O64390 — 0.994 O64390 →
Q7M753 — 0.994 Q7M753 →
Q1WM16 — 0.994 Q1WM16 →
P17709 — 0.993 P17709 →
O74962 — 0.993 O74962 →
Q9T079 — 0.992 Q9T079 →
Q93170 — 0.992 Q93170 →
Q9SEK2 — 0.992 Q9SEK2 →
Q9LPS1 — 0.992 Q9LPS1 →
Q6Q8A5 — 0.992 Q6Q8A5 →
P78875 — 0.991 P78875 →
Q9SHG0 — 0.991 Q9SHG0 →
Q2KNB5 — 0.991 Q2KNB5 →
Q9NFT7 — 0.991 Q9NFT7 →
Q9T071 — 0.991 Q9T071 →
Q6CUZ3 — 0.991 Q6CUZ3 →
Q02155 — 0.991 Q02155 →
B9KHF1 — 0.991 B9KHF1 →
Q9SEK3 — 0.990 Q9SEK3 →
Q16P87 — 0.990 Q16P87 →
Q5PBX6 — 0.990 Q5PBX6 →